Venture capital advisory
For research-driven ventures at the point where the science is real and the company is not yet obvious — academic spin-outs, translational programmes, first institutional rounds.
Early-stage ventures built on research have a particular problem: the work that makes them valuable is the work investors find hardest to price. A promising result is not a product, a principal investigator is not a management team, and the gap between them is where most translational projects stall. The advisory work is about closing that gap credibly — often using non-dilutive funding to do it.
What this involves
Built for translational work
Academic spin-outs and research programmes have different constraints from ordinary startups — institutional IP, founder time, publication timelines.
The bridge from grant to round
Federal funding can carry a technology to the point where a venture round is a reasonable conversation. Planning that path is the work.
Investors who understand the science
Deep-tech and life sciences investors underwrite differently. The relevant list is short and specific.
Honest staging
Raising too early is expensive in dilution and credibility. Being told to wait, and what to do meanwhile, is a real outcome.
From research to venture
The usual sequence for a research-driven venture is to use non-dilutive funding to answer the questions an investor would otherwise discount the company for — feasibility, manufacturability, a regulatory path, a first external validation — and only then raise.
That sequencing is deliberate. Each federal phase completed is a question an investor no longer has to take on faith, and the terms available reflect it.
Working with institutions
Spin-outs from universities and research institutes carry constraints ordinary startups do not: institutional IP ownership, licensing terms negotiated with a technology transfer office, conflict-of-interest rules governing faculty involvement, and publication timelines that interact with patent filing.
None of it is insurmountable, but it has to be resolved before an investor conversation rather than during diligence, where it reads as an unquantified risk.
Common questions
How early is too early?
If the honest answer to "what would have to be true for this to work" is still mostly unknown, that is usually a question for non-dilutive funding rather than a venture round. Raising against unanswered feasibility questions is expensive.
Do you work with university spin-outs?
Yes, and they are a substantial part of the early-stage work. The IP position and the technology transfer terms usually need settling before anything else is useful.
Do you take equity as a fee?
Engagements are fee-based and agreed in advance. Any other arrangement would be documented explicitly, and both sides should have their own counsel look at it.